article thumbnail

How to Fairly Allocate Scarce COVID-19 Therapies

Bill of Health

To allocate COVID-19 vaccines, the CDC’s Advisory Committee on Immunization Practices , the National Academies of Sciences, Engineering and Medicine (NASEM), and the World Health Organization (WHO) identified ethical goals for prioritization, such as maximizing benefit and minimizing harm, mitigating health inequities, and reciprocity.

COVID-19 209
article thumbnail

Health Disparities and the Risks of Social Determinants for COVID-19 – 14 Months of Evidence

Health Populi

ASPE analyzed data from 62,451,150 people who had 1 or more vaccine doses administered by 3-10-21. who had received 1 or more doses of COVID-19 vaccines by race/ethnicity were: 66% of White, non-Hispanic people (60% of U.S. of Hispanic and LatinX people (19% of U.S. The percentages of people in the U.S.

COVID-19 162
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Health Disparities in America: JAMA Talks Structural Racism in U.S. Health Care

Health Populi

For Black patients, lower utilization of ambulatory care and higher use of inpatient, emergency department, and nursing suggest greater spender downstream that might be prevented by more spending upstream on primary care, prevention, and early detection of disease. than on white people.

COVID-19 133
article thumbnail

Learning from the ‘COVID War’

Bill of Health

They fail to discuss and analyze the actions of nurses and other health care workers to organize care, to support each other when sick, and to force hospital managements to procure PPE like masks. COVID ravaged prison populations, nursing homes and the homeless with particular ferocity.

article thumbnail

The 2021 Shkreli Awards: Lown Institute Counts Down the Top 10 Healthcare Industry Abuses in the Coronavirus Pandemic

Health Populi

2: Moderna, funded with nearly $1 billion in taxpayer dollars to develop a COVID-19 vaccine, sets the highest prevailing market price for the product. The controversy here is that this was the highest price set although the company received 100% of the development costs for the vaccine covered by the U.S.